SciSparc Ltd. Announces Proposed Underwritten Public Offering of Approximately $1.3 Million

About this update from Scisparc Ltd.

[{"type":"text","content":"TEL AVIV, Israel, Aug. 09, 2023 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“SciSparc” or the “Company”) today announced that it intends to offer its securities in a firm commitment underwritten public offering. The Company intends to use the net proceeds from this offering for working capital. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. In addition, the Company expects to grant Aegis Capital Corp. a 45-day option to purchase additional ordinary shares of up to 15% of the number of ordinary shares sold in the offering solely to cover over-allotments, if any. Aegis Capital Corp. is acting as the sole book-running manager for the offering. This offering is being made pursuant to an effective shelf registration statement on Form F-3 (No. 333-269839) declared effective by the U.S. Securities and Exchange Commission (the \"SEC\") on February 23, 2023. A preliminary prospectus supplement and accompanying shelf prospectus describing the terms of the proposed offering will be filed with the SEC and will be available on the SEC's website located at http://www.sec.gov. Electronic copies of the preliminary prospectus supplement and the accompanying shelf prospectus may be obtained, when available, by contacting Aegis Capital Corp., Attention: Syndicate Department, 1345 Avenue of the Americas, 27th floor, New York, NY 10105, by email at [email protected], or by telephone at (212) 813-1010. Before investing in this offering, interested parties should read in their entirety the prospectus supplement and the accompanying prospectus and the other documents that the Company has filed with the SEC and that are incorporated by reference in such prospectus supplement and the accompanying prospectus, which provide more information about the Company and such offering. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. About SciSparc Ltd. (Nasdaq: SPRC): SciSparc Ltd. is a specialty clinical-stage pharmaceutical company led by an ...

More updates from Scisparc Ltd.